Trial intelligence / Profile preview

Lanreotide Autogel 120 mg in Active Acromegaly

NCT00499993Phase 3Completed

Sponsor
Ipsen
Start
Jan 2001
Modality
Peptides
Countries
1
01

Overview

A Phase 3 trial of lanreotide in acromegaly, sponsored by Ipsen. Started Jan 2001; status: completed.

02

Drugs

lanreotide
03

Conditions

acromegaly

Beyond the preview

Go deeper on NCT00499993.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00499993.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call